Literature DB >> 12416742

Rapid proliferation of a different clone early after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.

Takehiko Mori, Junichi Tamaru, Michihide Tokuhira, Shigehisa Mori, Hiroshi Suzuki, Toru Abe, Tsutomu Takeuchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12416742     DOI： 10.1007/bf02982801

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

1.  T-helper (Th)1/Th2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma.

Authors:  T Mori; R Takada; R Watanabe; S Okamoto; Y Ikeda
Journal:  Cancer Immunol Immunother       Date:  2001-12       Impact factor: 6.968

2.  Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells.

Authors:  T Marafioti; M Hummel; I Anagnostopoulos; H D Foss; B Falini; G Delsol; P G Isaacson; S Pileri; H Stein
Journal:  N Engl J Med       Date:  1997-08-14       Impact factor: 91.245

3.  Risk of second cancers after treatment for Hodgkin's disease.

Authors:  M A Tucker; C N Coleman; R S Cox; A Varghese; S A Rosenberg
Journal:  N Engl J Med       Date:  1988-01-14       Impact factor: 91.245

4.  Mantle cell (previously centrocytic) lymphomas express VH genes with no or very little somatic mutations like the physiologic cells of the follicle mantle.

Authors:  M Hummel; J Tamaru; B Kalvelage; H Stein
Journal:  Blood       Date:  1994-07-15       Impact factor: 22.113

5.  Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes.

Authors:  J Tamaru; M Hummel; M Zemlin; B Kalvelage; H Stein
Journal:  Blood       Date:  1994-08-01       Impact factor: 22.113

6.  An adult patient with hypersensitivity to mosquito bites developing mantle cell lymphoma.

Authors:  T Mori; S Okamoto; S Kuramochi; Y Ikeda
Journal:  Int J Hematol       Date:  2000-04       Impact factor: 2.490

Review 7.  Tumors of the immunocompromised patient.

Authors:  I Penn
Journal:  Annu Rev Med       Date:  1988       Impact factor: 13.739
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.